Reagents for fractionating target proteins from complex biological fluids, such as plasma, serum, CSF, urine or other tissue or cellular sources, and the subsequent chemical analysis of compounds physiologically associated with abundant proteins including proteins, peptides, fatty acids, hormones, glycosylation states, phosphorylation states, etc; Reagents for diagnosis of diseases associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; Immunoaffinity reagents for developing chemical markers that indicate the presence of disease states associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; Reagents for determining biological targets for drugs, namely determining biological processes that are susceptible to being affected by drugs in order that the drugs may alleviate disease states and conditions related to albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3 and associated compounds in humans and animals; Reagents for determining protein and peptide sequences for the purposes of identifying protein or peptide drug targets associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3, all for research use

Product development, medical and laboratory research in the field of proteomics, namely the science, system, components, organization, function, and biomedical applications of separation of abundant proteins, especially, in the area of proteomics sample processing that permits highly selective separation of abundant proteins, such as albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; development of chemical markers that indicate the presence of disease states; determining biological targets for drugs, namely determining biological processes that are susceptible to being affected by drugs in order that the drugs may alleviate disease states and conditions in humans and animals; determining protein and peptide sequences for the purposes of identifying protein or peptide drug targets; developing methodologies relating to the previous services such as developing bioanalytical methods to increase sensitivity, specificity and throughput of identifying and characterizing biological substances such as protein, peptides, hormones, lipids, used as biomarkers for a diagnosis or as drug targets